0 citations0 references

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

Bone Marrow Transplantation2016Vol. 51(6), pp. 786–792

Citations Over TimeTop 1% of 2016 papers

for the European Society for Blood and Marrow Transplantation (EBMT), Jakob Passweg, Helen Baldomero, Peter Bader, Chiara Bonini, Simone Cesaro, Peter Dreger, Rafael F. Duarte, Carlo Dufour, Jürgen Kuball, Dominique Farge, Andrew R. Gennery, Nicolaus Kröger, Francesco Lanza, A Nagler, Anna Sureda, Mohamad Mohty

Abstract

A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.

Related Papers

→ Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm(2015)19 cited
→ Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease(2013)5 cited
Clinical analysis of myeloproliferative neoplasm with stroke(2010)
Clinical analysis of 276 cases of aplastic anemia(2005)
→ Symptom load assessment of Ph chromosome/BCR-ABL fusion gene negative myeloproliferative tumor patients at different efficacy evaluation periods(2019)